Is Plexus Corp. (NASDAQ:PLXS) a buy in 2026?
Hold. Plexus Corp. is a wait-and-watch at today's price, not a fresh buy.
Quality manufacturing partner riding aerospace and medtech reshoring, but the easy money got made between $115 and $280.
Where PLXS is headed
Plexus has spent the last decade making itself indispensable to a very specific kind of customer: the one who cannot afford a recall. Surgical robots, infusion pumps, defense avionics, semiconductor capital equipment. These are not the customers that shop EMS providers on basis points. They want a partner who can hold a build for fifteen years, navigate FDA Class III paperwork, and bring up a Penang line in six months when Mexico capacity gets tight. That positioning is finally showing up in the numbers, with revenue growth running near 19% and a backlog that reflects the post-2024 reshoring wave hitting healthcare and aerospace simultaneously.
Read the full Compass Direction on PLXS
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $258.37).
See the full PLXS analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Plexus Corp. (NASDAQ:PLXS) a buy in 2026?
Hold. Plexus Corp. is a wait-and-watch at today's price, not a fresh buy. Quality manufacturing partner riding aerospace and medtech reshoring, but the easy money got made between $115 and $280.
What is PLXS's Compass Score?
Plexus Corp. scores 82/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for PLXS?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the PLXS page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.